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Abstract
Leishmaniasis is a vector-borne tropical/subtropical disease caused by an intra-
cellular parasite transmitted to humans by sand fly bite. It is endemic in Asia,
Africa, the Americas, and the Mediterranean region. Worldwide reports include
1.5–2 million new cases each year, more than 300 million at risk of acquiring the
disease, and 70,000 deaths per year. Clinical features depend on the Leishmania
species and immune response of the host, varying from localized cutaneous disease
to visceral form with potentially fatal outcome; however, the common presentation
is either cutaneous, mucocutaneous, or visceral leishmaniasis. Many therapeutic
agents are being used in Leishmania treatment, but the only effective treatment is
achieved with current pentavalent antimonials. WHO considers Leishmaniasis as
one of the “Neglected Tropical Diseases” that continues to be prevalent despite
international, national, and local efforts towards its control and elimination over the
last decade. This chapter reviews the global perspective of Leishmaniasis with
increasing recognition of emerging “Atypical forms” and new surge of disease
across the world mainly due to increasing conflicts in endemic areas leading to
forced migration among other causes. All these challenges related to environment,
disease, and vector pose major implications on WHO’s leishmaniasis control and
elimination plan.
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1. Introduction
Leishmaniasis is a vector-borne disease caused by an obligate intracellular pro-
tozoa of genus Leishmania and is transmitted by the bite of a female phlebotomine
sand fly (Figure 1). It is a poverty-related disease with an estimated 0.7–1 million
new cases reported per year from approximately 100 endemic countries. It is
reported from all continents except Australia and Antarctica.
The disease is primarily zoonotic with exception of L. donovani and L. tropica,
although some evidence exists that animal reservoir exists for these species too.
There are about 53 species of Leishmania described with more than 20 species
pathogenic to humans and each distinct species causing different clinical manifes-
tations ranging from self-resolving cutaneous ulcers to disfiguring mucocutaneous
lesions to life-threatening systemic visceral disease [1–3]. The outcome depends on
multiple factors including parasite characteristics, vector itself, and host factors in a
particular patient’s immune status. The World Health Organization (WHO) con-
siders leishmaniasis as not only one of the neglected tropical diseases but also a
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public health problem that requires elimination by developing effective therapeutic
regimens and prevention/control plans.
2. Epidemiology
The disease classification is complex and can be characterized by either its
clinical presentation into cutaneous (localized or disseminated), mucocutaneous,
and visceral or geographic location into Old World leishmaniasis mainly including
Africa, Asia, the Middle East, the Mediterranean, and India or New World leish-
maniasis including Central and South America (Table 1) [4–6].
More than 90% of the cases of visceral leishmaniasis (VL) cases worldwide were
reported from 7 countries in 2015 including Brazil, Ethiopia, Kenya, India, Somalia,
Sudan, and South Sudan; however, the disease remains endemic in more than 60
countries [1]. The Indian subcontinent accounts for almost 70% of the world’s
anthroponotic visceral leishmaniasis cases, India having the highest incidence
Figure 1.
This photograph depicts a right lateral view of a Phlebotomus papatasi sand fly which had landed atop the
skin surface of a human volunteer. This specimen had just completed its ingestion of its blood meal, which is
visible through its distended transparent abdomen. Sand flies like this P. papatasi are responsible for the spread
of the vector-borne, parasitic disease, leishmaniasis (courtesy of Centers for Disease Control and Prevention/
prof. Frank Hadley Collins and James Gathany) (https://phil.cdc.gov/Details.aspx?pid=10276).
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followed by Nepal and Bangladesh. In immunocompromised patients, Leishmania
parasites can persist for decades after management and may reappear exhibiting
fulminant reactivation when immunity is compromised. Between 5 and 50% of
Table 1.
Leishmania taxonomy showing most of the clinically significant Leishmania species [1, 5, 6, 14].
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treated VL cases may develop post-kala-azar dermal leishmaniasis (PKDL),
depending on geographic location, secondary to the interferon gamma-driven
immune response against dermal parasite [7–9].
More than 90% of cutaneous leishmaniasis (CL) and mucocutaneous leishman-
iasis (ML) cases are reported from Pakistan, Afghanistan, Syria, Saudi Arabia, Iran,
Brazil, Algeria, and Peru. The number of reported VL cases has decreased substan-
tially in the past decade most likely due to early diagnosis and better access to
treatment. In East Africa, however, the fatal disease case number continues to be
sustained. However there is a surge in endemic CL across the world predominantly
due to increased conflicts with forced displacement of population and living in poor
sanitary conditions. In addition, there is also an increase in the number of overall
Leishmania cases reported worldwide and increased new cases reported from
nonendemic areas [10–12]. A renaissance of CL is seen in conflict areas of Middle
East in particular Syria mainly due to collapse of public health systems, exposure of
nonimmune population, and poor living conditions.
2.1 Risk factors
Population migration of susceptible individuals in endemic areas as well as into
nonendemic areas, malnutrition, poverty, and immune status of the host play a
major role. Temperature is another important factor as Leishmania species for
cutaneous disease grow best at lower temperature, while species causing VL grow
better at core temperatures.
The pathogenesis appears related to T-cell cytotoxicity. The promastigotes acti-
vate complement system through alternate pathway with suppression of cell-
mediated immunity against the organism. In self-resolving and asymptomatic
patients, T helper type 1 cells (Th1) predominate with interleukin-2 (IL-2), inter-
feron gamma, and IL-12 as important cytokines helping with disease resolution. In
visceral and diffuse cutaneous forms, T helper type 2 cells (TH2) predominate with
patients exhibiting anergy to the organism. These cells secrete IL-4, IL-5, IL-9, IL-
13, and IL-17E/IL-25.
A susceptibility gene in band 22q12 is identified in parts of Sudan with high
prevalence of VL [13].
Coinfection of VL with HIV is a major challenge. Both infections share a com-
mon immunopathologic mechanism involving macrophages and dendritic cells of
reticuloendothelial system, therefore leading to an accelerated progression of both
diseases in coinfection.
3. Life cycle
Leishmania is scientifically classified as a “genus” that belongs to the “order” of
Trypanosomatidae family, under the “class” of Kinetoplastea, under the “phylum”
of Euglenozoa. The parasite Leishmania exists in two forms: flagellated promastigote
form in sandflies and cultures and nonflagellated amastigote form in animals and
humans (Figure 2) [14, 15]. The sandflies acquire infection when they bite an
animal or human host. The parasite develops over 4–25 days in the sandflies and
transforms into a promastigote form where they multiply by binary fission in
the midgut and move upwards to the pharynx. Infection is transmitted mainly
during days 6–9 after ingestion when there is heavy pharyngeal infection and
promastigotes are regurgitated via a bite to the host. The sand fly can regurgitate
more than 1000 parasites per bite. In the host some of the flagellates are destroyed,
whereas others enter intracellular lysosomal organelles of macrophages of
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reticuloendothelial system. The flagella of the organisms are lost, and amastigotes
are formed that continue to multiply until the infected host cells get filled with
organisms and rupture releasing free amastigotes that invade new cells, thus
continuing the vicious cycle of Leishmania infection (Figure 2). The incubation
period depends on the individual parasite species. In certain geographic areas, the
transmission cycle can be maintained by the infected animals and does not require
infected humans. In other areas where disease transmission has the anthroponotic
cycle via humans, the disease transmission can be controlled by effective treatment
of infected patients [16].
3.1 Mode of transmission
The disease is mainly transmitted by the bite of a 2–3 mm in size female
“Phlebotomus sand fly” in OldWorld leishmaniasis and Lutzomyia in the NewWorld
disease. There are approximately 20 pathogenic Leishmania species and up to 500
known phlebotomine sand fly species identified as vectors of disease [17, 18].
The disease is mostly zoonotic with humans being incidental hosts infected by
sand fly bite.
4. Clinical presentation
In addition to the known classic disease spectrum and clinical presentations, new
unusual and atypical forms are emerging which is adding to the complexity of
achieving control and disease eradication goal [19].
4.1 Cutaneous leishmaniasis
CL causing Leishmania parasites are divided into New world and Old world
species. The NewWorld species affect mainly Central and South America and include
L. amazonensis, L. braziliensis, L. mexicana, and L. guyaensis, among others. The Old
World species examples include L. tropica, L. major, and L. aethiopica that are com-
mon in the Indian subcontinent, the Middle East, the Mediterranean basin, and East
Figure 2.
Leishmania life cycle.
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Africa. CL is usually a limited cutaneous disease. The lesions develop as papules at the
sand fly bite site and progress over weeks to months to develop larger nodules that
eventually ulcerate (Figure 3). Lesions are often itchy and may have a hyperkeratotic
wart-like appearance. These lesions often self-heal in 2–18 months, leaving a perma-
nent, often disfiguring, scar, leading to major cosmetic concern and social stigma.
Approximately 10% of CL cases may progress to severe disease such as diffuse
CL, ML, disseminated CL, and/or L. recidivans [1, 20].
4.1.1 Uncommon variants of CL
Uncommonly, CL variants are encountered that are associated with various
underlying immune responses.
L. recidivans typically follows a healed L. tropica cutaneous infection and pre-
sents as new lesions encircling the old scar. The lesions show predominantly
Figure 3.
This photograph depicts the volar surface of a patient’s extended right arm, who had been ill with leishmaniasis,
having been infected with Leishmania sp. protozoa, which had manifested itself as a cutaneous form of the
disease (courtesy of Centers for Disease Control and Prevention/Dr. martins Castro and Dr. Lucille K. Georg)
(https://phil.cdc.gov/Details.aspx?pid=12161).
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increased number of lymphocytes making it difficult to histologically distinguish
from tuberculosis.
Diffuse cutaneous leishmaniasis presents with multiple widespread nontender,
non-ulcerating lesions, resembling lepromatous leprosy, and a negative leishmanin
skin test (LST). The skin is heavily infiltrated by organisms and the patients lack a
cellular immune response. These are caused by L. amazonensis, L. aethiopica, and L.
mexicana.
Disseminated cutaneous leishmaniasis presents with 10 or more mixed-type lesions
in multiple body parts and is mostly seen in Latin America with frequent involve-
ment of the mucosa. Histologically, the organisms are scant in the skin lesions, and
patients show positive antibodies against Leishmania and positive LST test.
Most cases of diffuse cutaneous leishmaniasis and L. recidivans are chronic and
resistant to treatment, may be exceedingly disfiguring, and can be associated with
low mortality rates.
L. infantum/L. chagasi predominantly causes VL; however, it may lead to atypi-
cal cutaneous disease. Reported cases are autochthonous, seen in immunocompe-
tent hosts, and diagnosed in different regions [19].
L. donovani is also mainly responsible for VL; however, some atypical autoch-
thonous CL cases by L. donovani are reported [19].
4.2 Mucocutaneous leishmaniasis
ML presents as destructive lesions involving oronasal mucosa with involvement
of the nasal septum, lips, and palate. Ninety percent of ML cases show a previous CL
scar. The disease is often chronic and progressive with destructive, disfiguring
midfacial lesions leading to extensive mutilation. Secondary infection and respira-
tory tract invasion may lead to patient’s demise. It is frequently seen in immuno-
compromised individuals and being a potentially life-threatening disease requires
immediate/early diagnosis and treatment [21, 22]. Less than 5% of patients infected
by L. braziliensis and a small percent of those infected by L. panamensis and L.
guyanensis can develop mucosal involvement months to years after cutaneous dis-
ease resolution [13].
4.3 Visceral leishmaniasis
L. donovani is the main species causing VL and humans are the main reservoir
for it. L. infantum also causes visceral disease; however, it is zoonotic. VL is charac-
terized by a “pentad” of persistent irregular fever, hepatosplenomegaly, weight
loss, pancytopenia, and hypergammaglobulinemia. The fever characteristically
shows a double rise in 24 hours with spikes of fever and afebrile intervals in
between. It is the most devastating and fatal forms of leishmaniasis. The spectrum
ranges from asymptomatic infection to fulminant life-threatening disease. The dis-
ease may present with an acute or insidious onset, however the typical presentation
is that of wasted, thin, cachectic appearance with prominent abdominal distention
due to hepatosplenomegaly. Jaundice is considered to be a bad prognostic sign. The
incubation period is 2 weeks–8 months. High parasite burden is often associated
with malnutrition and wasting in particular in children [23, 24]. VL is often associ-
ated with hyperpigmentation of the skin most likely secondary to production of
adrenocorticotropic hormones. In such cases it is referred to as kala-azar/black fever
[25]. VL, if untreated, is fatal within 2 years; mortality is mostly due to secondary
bacterial infection, immunosuppression, hemorrhage due to hematopoietic
infiltration, and severe anemia [13].
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4.3.1 Uncommon variants of VL
Gulf War soldiers: An uncommon form of VL is described in some US veterans
who were infected while participating in Gulf war. These patients had only mild
symptoms and light parasitic burden. L. tropicawas identified as the causative agent
in some of these cases [19, 26].
Viscerotropic leishmaniasis: This is an indolent form of disease that has a distinct
clinical presentation; however it does not progress to or develop classic VL.
VL-HIV coinfection: HIV is considered to be responsible for the re-emergence of
the VL. Both organisms share common pathologic immunologic system involving
the reticular endothelial system, therefore leading to accelerated progression of the
disease. VL in an HIV-infected person should be considered an acquired immune
deficiency syndrome (AIDS)-defining illness, and HIV testing should be mandatory
in all patients presenting with VL [1, 27]. Atypical disseminated leishmaniasis can
be seen in these patients with lesions involving the gastrointestinal tract and the
respiratory tract [21, 28].
L. tropica, L. amazonensis, and L. major generally associated with CL are
reported to be viscerotropic and uncommonly may lead to visceral disease [19].
4.4 Post-kala-azar dermal leishmaniasis
PKDL was commonly seen in India and Africa as a late complication of VL
secondary to L. donovani and rarely L. infantum, the latter typically in immuno-
compromised patients [29]. Patients often present months to as many as 20 years
after VL with hypopigmented or erythematous skin lesions which over time
progress to develop plaques and nodules over the face and trunk. These lesions
are often nontender and have preserved sensation, a feature distinguishing this
from lepromatous leprosy. The lesions often resolves spontaneously;
however, relapse is common, and resistant forms to antimonial treatment have
been reported [1, 13].
5. Diagnosis
Centers for Disease Control and Prevention (CDC) has a practical guide for
laboratory diagnosis of leishmaniasis at http://www.cdc.gov/parasites/leishmania
sis/health_professionals/index [18].
Cutaneous and mucocutaneous lesions usually show normal values in routine
laboratory testing. VL, on the other hand, may exhibit normocytic normochromic
anemia, leukopenia, and/or thrombocytopenia due to bone marrow or spleen
involvement. In addition there may be involvement of other organs leading to their
respective abnormal functions such as abnormal liver function test in patients with
significant hepatic disease.
Characteristically the diagnosis is confirmed by visualizing the amastigote form
of the protozoa from infected tissue by performing invasive procedure such as
dermal scraping or biopsies for cutaneous lesions and/or fine-needle aspirates/
biopsies for visceral disease (Figure 4). The smears are often stained with Giemsa,
Leishman, and/or Wright’s stain and slides reviewed under oil immersion. Histori-
cally, splenic puncture was considered the most sensitive method and golden stan-
dard procedure; however it is potentially life-threatening, carries a high risk of
complications such as hemorrhage, and therefore currently is considered unneces-
sary. In endemic areas with high clinical suspicion, clinical history and physical
examination is often sufficient to reach the diagnosis. Since the localized disease has
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prominent cell-mediated immunity to the organism, especially when long-standing,
isolation, identification, and culture of these organisms can be extremely challeng-
ing. In cutaneous disease the organism may be visualized in samples obtained by
biopsy, scraping, or FNA in approximately 70% of cases, while the culture from the
skin shows only 40% sensitivity [13, 30].
A skin punch biopsy is recommended for the CL to be taken from the raised edge
of an active lesion where parasites exist. In addition to the formalin-fixed sections,
touch preparations/tissue impression slides can also be prepared and examined. The
diagnostic finding is to identify the amastigotes with their eosinophilic rod-like
cytoplasmic kinetoplast (Figures 5 and 6). In long-standing lesions, biopsy of the
necrotic center of the lesion, and cases with low burden disease, the biopsy may
show false-negative results.
Mucosal biopsies and/or dental scrapings are used for mucocutaneous lesions to
look for organisms.
Invasive procedures such as aspirates or biopsies from the spleen, bone marrow,
lymph node, and/or liver were used to diagnose VL. However, technology
advancement and development of rapid diagnostic tests (RDT) such as recombinant
K39 assay with its high sensitivity and specificity made the above invasive pro-
cedures unnecessary. In general, the positivity rate for identification of amastigotes
in splenic aspirate is 98% and in bone marrow aspirate/biopsy is 54–86% [31, 32].
Blood samples, except in HIV-infected patients, and lymph nodes have lower
sensitivity.
Leishmanin skin test/Montenegro skin test, similar to purified protein derivative
(PPD) test used forMycobacterium tuberculosis, is a marker of cellular immune
response and tests for delayed-type hypersensitivity reaction. The test uses injection
of killed promastigotes in the skin. If there is a skin induration of at least 5 mm after
48–72 hours, the test is considered positive. The test is negative in acute infection as
it shows positive results after 2–3 months of infection. In addition the test is nega-
tive in active VL and immunosuppressed patients due to anergic response. In the
United States, no skin tests for leishmaniasis are approved because of lack of
standardization; however, it is used in developing countries and is useful in epide-
miological surveys as a marker of previous exposure [1].
Figure 4.
This photomicrograph of a subcutaneous tissue sample reveals the presence of numerous Leishmania donovani
parasites (courtesy of Centers for Disease Control and Prevention/Dr. Martin D. Hicklin) (https://phil.cdc.gov/
Details.aspx?pid=330).
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Several serological assays for detection of antibodies against leishmaniasis
have been developed using various techniques such as direct agglutination
(DAT), immunofluorescence assay (IFA), enzyme-linked immunosorbent
Figure 6.
This is a transmission electron microscopic image of Leishmania major amastigotes, which had been grown in
a cell culture. Note the dense kinetoplasts in the cytoplasm (courtesy of Centers for Disease Control and
Prevention/Cynthia goldsmith and Luciana Flannery) (https://phil.cdc.gov/Details.aspx?pid=22001).
Figure 5.
This photomicrograph depicts some of the histopathologic details seen in a canine bone marrow smear, processed
using Giemsa stain, in the case of leishmaniasis. This particular view displays Leishmania donovani parasites
contained within one of the bone marrow histiocytes (courtesy of Centers for Disease Control and Prevention/Dr.
Francis W. Chandler) (https://phil.cdc.gov/Details.aspx?pid=30).
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assay (ELISA), and western blot. Although these tests show high sensitivity for
acute VL, they are not specific for this disease and may show false positivity with
other organisms.
Detection of antibodies to recombinant K 39 antigen appears to correlate with
active VL disease in species such as L. donovani, L. chagasi, and L. infantum. These
RDTs however are not useful in cutaneous and mucocutaneous infection. Based on a
Cochrane review of RDTs, the sensitivity for rK39 RDT assay is excellent at 97% in
Indian subcontinent but low in East Africa and Sudan at 85%. More recently, an
rK28 antigen-based RDT shows better sensitivity in Sudan [33, 34]. Recent efforts
in developing tests that detect antigens show promising results but still with
certain limitations; latex agglutination test has moderate sensitivity of 64% and
higher specificity of 93%, while most recent ELISA test shows more than 90%
sensitivity [1, 35].
Molecular techniques including polymerase chain reaction (PCR), with signifi-
cant advances in technology, show higher sensitivity; however, due to the higher
cost and complexity of the procedure, they are not available in resource-limited
settings. This is particularly true in VL. These tests have a higher sensitivity for
cutaneous lesions: reverse transcriptase loop-mediated isothermal amplification
(LAMP) technology exhibiting a sensitivity of 98% in CL.
6. Treatment
Multiple factors play a role in treatment decision-making for Leishmania that
include the specific species, geographic location, comorbidities, and the type of
disease whether CL, ML, PKLD, or VL. On most part, it is considered as a treatable
and curable disease; however it requires an immunocompetent system. Despite
multiple efforts and after all these years, the treatment of Leishmania still remains a
problem. This is mostly because of indiscriminate treatment leading to frequent
emergence of parasite resistance, and the side effects of antileishmanial
therapeutic agents call for a search for alternative treatment including the use of
natural products such as plants and herbs [36]. Traditionally, medicinal plants have
been used throughout the history and are still being used as an alternative
therapy to conventional health care, in particular in developing countries and
mainly in rural areas that are often deprived of public health resources [37]. This
science of using medicinal plants as therapeutic agents is referred to as
phytotherapy [38]. The alternate therapies, when studied, show different mecha-
nisms of action. Plants have several secondary metabolites, for example, flavonoids,
polysaccharides, lactones, alkaloids, diterpenoids, and glycosides that may activate
the immunological system [39]. As an example, a combination of miltefosine and
nanoparticles of curcumin, a component of turmeric, displayed lymphocyte prolif-
eration and increased the phagocytic capacity of peritoneal macrophages [40].
Another example is tricin which is isolated from Casearia arborea, an evergreen
tea, that was reported to modulate the respiratory burst, thus helping in parasite
elimination.
Other mechanisms reported as possible mechanisms of action include reactive
oxygen species generation and apoptosis-inducing potential. Examples of the latter
include ethanolic extract of seeds and leaves of Azadirachta indica and essentials oils
of Artemisia campestris and Artemisia herba-alba that act as an apoptosis inductor in
promastigotes of L. donovani and L. infantum [36].
Several studies have been carried out to assess the efficacy of such alternate
treatment; however, the results have not been very encouraging. Most of the plants
show immunomodulatory effect, but no leishmanicidal effect has been validated,
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supporting the notion that substances obtained from plants may complement the
treatment of leishmaniasis because of their immunomodulatory effects, but there is
no direct effect against the parasite.
There are recommended guidelines for Leishmania treatment by the WHO [16].
In addition, a panel of the Infectious Diseases Society of America (IDSA) and the
American Society of Tropical Medicine and Hygiene (ASTMH) have developed
management guidelines for Leishmania patients. These guidelines are mainly for
physicians practicing in North America and are based, whenever possible, on ran-
domized clinical trials and a systematic method of grading the quality of evidence
and strength of recommendation [41].
6.1 Cutaneous leishmaniasis
Most CL cases spontaneously regress in immunocompetent hosts over 2–
18 months, and therefore conservative approach can be used in particular for those
caused by L. major and L. mexicana. On the other hand, L. braziliensis has a low
spontaneous cure rate. The decision to treat CL and ML is often to reach a goal of
reducing the risk of disfigurement, scarring, dissemination, accelerating cure, and
subsequent progression to mucocutaneous disease in cases of CL. In addition it is
important to classify cutaneous lesions into simple or complex cutaneous lesions
based on certain criteria that are then used for treatment decision-making process.
These include immunocompetent versus immunocompromised host status, regional
lymphadenopathy, multiplicity of lesions (>4), lesions of >5 cm in size, lesions on
sensitive areas (such as face, ears, eyelids, lips, fingers/toes, genitalia, or joints),
more than 6 months duration, and Leishmania species that are more likely to be
associated with ML, unusual presentations such as diffuse or disseminated CL, and
L. recidivans. Traditional treatment for CL has been intralesional injections mostly
sodium stibogluconate, thermotherapy, cryotherapy, and topical agents such as
paromomycin. The combination of intralesional antimonials and cryotherapy is
often the first-line treatment option for CL, resulting in higher cure rates. There has
been lack of standardization and poor trial designs for therapeutic regimens in the
past. Recently efforts are being carried out to develop unified criteria to define
measurable endpoints for different treatment regimens. The treatment regimen
decision regarding whether to give local or systemic therapy or choice of
therapeutic modality is based on the geographic location and the infecting
Leishmania species.
Local treatment includes a combination of intralesional antimonials and
cryotherapy, paromomycin ointment containing methylbenzethonium chloride,
paromomycin containing 0.5% gentamicin, and paromomycin with allopurinol for
L. recidivans.
Systemic regimens include oral fluconazole, pentavalent antimonials with or
without pentoxifylline, ketoconazole, miltefosine, liposomal amphotericin B
(LAMB), and pentamidine isethionate.
Systemic treatment for CL is usually used for immunosuppressed patients,
mucocutaneous lesions, diffuse/extensive lesions, and refractory disease. In addi-
tion infection by L. braziliensis and L. infantum should be considered for systemic
treatment (Tables 2 and 3) [1, 17, 18].
6.2 Mucocutaneous leishmaniasis
For mucocutaneous disease systemic regimens include pentamidine isethionate,
pentavalent antimonials + pentoxyfilline, and LAMB (Table 4) [17, 18].
12
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Table 2.
Treatment regimens for cutaneous leishmaniasis, New World species, as per WHO recommendations (adopted
from WHO) (https://www.who.int/leishmaniasis/research/978924129496_pp67_71.pdf?ua=1) [8].
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6.3 Post-kala-azar dermal leishmaniasis
Treatment regimens for PKDL are scant. In general, majority of cases from East
Africa are self-healing and therefore do not require treatment. In contrast, in the
Indian subcontinent, these patients are treated. Since vast majority of these patients
are healthy and the risk is cosmetic, the risk benefit should be weighed before
initiating therapy. Selected treatment regimens are recommended by the WHO,
Table 3.
Treatment regimens for cutaneous leishmaniasis, Old World species, as per WHO recommendations (adopted
from WHO) (https://www.who.int/leishmaniasis/research/978924129496_pp67_71.pdf?ua=1) [8].
14
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when patients require treatment, that include miltefosine, amphotericin B
deoxycholate, and LAMB mainly for Indian subcontinent. As for East Africa, the
WHO based on evidence grading recommends pentavalent antimonial, LAMB,
miltefosine, and combination treatment (pentavalent antimonial with
paromomycin) (Table 5) [17, 18].
6.4 Visceral leishmaniasis
Traditionally VL has been treated by pentavalent antimonials. Recently there is
emergence of resistance in the Indian subcontinent. Current recommendations for
VL in East Africa include pentavalent antimonials, LAMB, or combination treat-
ment (including pentavalent antimonials with paromomycin). As for the Indian
subcontinent, the recommendations include LAMB, amphotericin B deoxycholate,
miltefosine, and one of the combination therapies: LAMB with miltefosine, LAMB
with paromomycin, or miltefosine with paromomycin [1]. As for complicated VL,
elderly patients, and pregnant patients in East Africa, it is recommended to have
LAMB treatment because of its better safety. LAMB monotherapy is not
recommended in patients with less severe disease in Asia due to lack of proven
efficacy in that region [42]. In Asia, sodium stibogluconate, rather than LAMB, is
considered the first-line treatment for L. infantum and L. donovani. The WHO
recommended LAMB therapy in the initial elimination phase for L. donovani in
Table 4.
Treatment regimens for mucocutaneous leishmaniasis as per WHO recommendations (adopted from WHO)
(https://www.who.int/leishmaniasis/research/978924129496_pp67_71.pdf?ua=1) [8].
Geographic areas affected by post-
kala-azar dermal leishmaniasis
Recommended treatment regimens ranked by preference
East Africa 1.Pentavalent antimonials: 20 mg Sb5+/kg per day
intramuscularly or intravenously for 30–60 days, when
indicated (C)
2.Liposomal amphotericin B: 2.5 mg/kg per day by
infusion for 20 days, when indicated (C)
Bangladesh, India, and Nepal 1.Amphotericin B deoxycholate: 1 mg/kg per day by
infusion, up to 60–80 doses over 4 months (C)
2.Miltefosine orally for 12 weeks at dosage as above in
visceral leishmaniasis (A)
Table 5.
Treatment regimens for post-kala-azar dermal leishmaniasis as per WHO recommendations (adopted from
WHO) (https://www.who.int/leishmaniasis/research/978924129496_pp67_71.pdf?ua=1) [8].
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Table 6.
Treatment regimens for visceral leishmaniasis as per WHO recommendations (adopted from WHO) (https://
www.who.int/leishmaniasis/research/978924129496_pp67_71.pdf?ua=1) [8].
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the Indian subcontinent; however currently several combination regimens are
available which will alleviate the risk of resistance development to LAMB
therapy (Table 6) [17, 18].
6.5 Human immunodeficiency virus (HIV): Visceral leishmaniasis coinfection
VL should be treated as an opportunistic infection if diagnosed in patients with
HIV, warranting lifelong antiretroviral therapy regardless of CD4 count [27]. The
core infected patients require longer treatment with higher doses since they are at a
higher risk for disease relapse, poor outcome, and increased mortality. In addition,
developing VL disease in HIV patients adversely affects their response to antiretro-
viral therapy [43]. Current WHO recommendation, so far, is LAMB for all regions.
Some cases may require combination treatment including LAMB with mitefosine,
pentavalent antimonials, and/or amphotericin B deoxycholate. Randomized control
trials are ongoing in both Ethiopia and India comparing combination of LAMB and
miltefosine with LAMB monotherapy [44, 45].
6.6 Surgical intervention
Surgical intervention is not the recommended modality of treatment in majority
of leishmaniasis cases; however, surgery may be required in certain cases such as
splenectomy in resistant disease, orofacial surgery for severely debilitating ML, and
cosmetic surgery for disfiguring cutaneous lesions.
7. Prevention and control
L. donovani is perhaps one of the most virulent Leishmania species and is present
in South Asian region, one of the highest incidence areas of VL. Between 2005 and
2013, Leishmania ranked the second worst next only to malaria among the 16
categories of “neglected tropical diseases” [46]. In 2005 the WHO and the govern-
ment representatives of India, Nepal, and Bangladesh signed a memorandum of
understanding with commitment to mutually cooperate in order to achieve VL
elimination from these countries by 2015. The objective was to reduce the annual
incidence of VL to below 1/10,000 inhabitants by 2015 using detection and treat-
ment of VL cases and vector control measures [47]. The target was not achieved by
the expected date of 2015 due to high cost and limited availability of treatment, lack
of effectiveness of vector control measures, emergence of parasite resistance, and
low community coverage of health services in all areas. A second target was set for
2017; however, the WHO has recently reset the target of VL elimination from the
Indian subcontinent to year 2020 [48]. In the Eastern Mediterranean region, a
specific target was set for CL to detect 70% of all cases and at least treat 90% of
them. There is crucial gap in planning elimination of VL in Asia and VL and CL in
other regions. These elimination campaigns will require more intense work and
better strategic planning in addition to the high cost required. Currently, there is
increased global awareness about the disease and the dire need for its elimination, in
particular, after Asian elimination initiative of VL and 2012 London declaration on
neglected tropical diseases. Having said that, many challenges still exist that
counteract these efforts. These include poor sanitary conditions, conflict zones
leading to forced migration, emerging atypical variants, poor public awareness
especially in nonendemic areas, suboptimal diagnostic modalities, and limited
treatment options [1, 49].
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7.1 Mass treatment
The VL elimination initiative in the Indian subcontinent in collaboration with
the WHO was based on diagnosis and treatment of VL patients using mass treat-
ment to reach the target of reducing the annual VL incidence to below 1/10,000.
This plan was dependent on actively looking for and diagnosing Leishmania
patients. However, the target date was missed because of several factors including
limitations of diagnostic tools to diagnose patients actively, lack of health-care
coverage in certain areas in developing countries in particular rural regions, lack of
proper vector control, and high cost and limited availability of treatment [46–48].
7.2 Vector control strategies
Including insecticide-treated nets and indoor insecticide sprays are used for
areas where sandflies bite indoor. Recently resistance to dichlorodiphenyltri-
chloroethane (DDT) is reported to emerge, and therefore other synthetic products
such as pyrethroids started to be used [50]. In areas like Africa where the vector
mainly bites outdoor, selective outdoor spraying might be effective in reducing
vector density. In addition alternative vector control measures have been proposed
and used such as plastering of walls and floors using mud and lime. However these
environmental management methods need further evaluation and validation. The
KALANET project was the only trial that evaluated the impact of “long-lasting
insecticidal nets” on L. donovani and concluded that these nets have beneficial
effects against L. donovani as they provide some degree of personal protection
against infection as compared to those using untreated nets or no nets. Further
prospective studies are needed to evaluate integrated vector management measures
on VL and other vector-borne diseases [47].
7.3 Reservoir eradication/control
In areas of zoonotic transmission should be effectively targeted to reduce the
human infection rate from infected animal reservoir. Several reservoir control
measures have been used including animal elimination in certain areas, canine
vaccines, and insecticides used on dogs such as spot-on insecticide which are drops
applied on skin under the hair in the neck region, insecticide-impregnated dog
collars, and whole body insecticide use. Studies on efficacy of animal reservoir
intervention programs are limited and show lack of generalizability of intervention
measures as well as mixed results [17]. In addition there are also conflicting results
on the impact of dogs in transmission of leishmaniasis since not all infected dogs
become infectious. All the above factors point towards a fundamental gap in our
knowledge of disease biology and its transmission.
7.4 Minimizing outdoor exposure
At dawn to dusk which are the peak bite times and use of insecticide-treated nets
and/or fine-mesh nets since the sandflies are small in size and can pass through
standard mosquito nets.
7.5 Transmission via blood
Infected patients should not donate blood or organs since the parasite can be
transmitted through blood.
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7.6 Immunization/vaccination
Several candidate vaccines are in preclinical development, and at least three are
currently in clinical studies; however, no effective vaccine has been identified to
date to effectively prevent human leishmaniasis [51]. Some studies show vaccina-
tion by killed Leishmania promastigotes, and live BCG can develop protection
against CL, but no protection is seen against VL. Approximately 90–98% of leish-
maniasis patients recover after disease and develop natural acquired immunity
mainly due to Th1 lymphocyte activation and its reaction towards the infecting
parasite. This strongly supports the ongoing vaccination development efforts,
hopefully looking forward for a clinically efficient vaccine to be available in the near
future.
All the above measures have shown some success; however, they are costly and
require extensive coordination efforts globally. Early diagnosis and treatment
remain the main control strategy since untreated patients serve as reservoirs of
parasites. In most countries majority of patients present themselves to the health
care, suggesting that many cases will remain in the community for long periods
before seeking health care due to reduced awareness. Strategy for eradication would
require surveillance with early detection and prompt treatment measures applied
globally, mostly in heavily infested areas.
7.7 Postinfection immunity
Successfully treated patients who receive full course of therapy by effective
agents and self-resolving infections generally acquire immunity from the infecting
species in 97–98% of the cases.
7.8 Long-term monitoring
Prolonged monitoring and follow-up evaluations of patients after successful
treatment are recommended for relapse or recurrence of the disease. Yearly follow-
up is recommended for patients infected with L. braziliensis for up to a decade for
early detection of any progression to mucocutaneous disease. Certain complex cases
of ML, diffuse CL, L. recidivans, and PKDL can be difficult to treat and may require
prolonged therapy. In addition, retreatment and/or second-line medications may be
required for patients with resistant disease.
8. Conclusion
There has been increasing global awareness about leishmaniasis and the need for
its eradication. However, there are many challenges that hinder this global initiative
and maintain leishmaniasis as one of the neglected tropical diseases. These chal-
lenges include but are not limited to high cost, variability of clinical spectrum, cyclic
transmission patterns, changing disease foci, emerging atypical and resistant forms,
suboptimal diagnostics, limited treatment options/availability, and suboptimal
community awareness and health-care coverage, in particular in nonendemic areas.
Several preventive measures using various strategies are needed to tackle personal
human protection against infection, interventions targeting vector and animal res-
ervoir control. With the current known challenges and limitations of resources,
perhaps integrated approach to control this infection and focus on development of
effective vaccine for protection may be a strategic way to use the limited resources
available to reach the WHO’s set target of leishmaniasis reduction/elimination [17].
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For WHO to reach its leishmaniasis elimination target, seriously committed global
efforts with substantial funding will be required. However, the question whether
complete accomplishment of this goal is technically achievable, given the
abovementioned challenges, remains to be answered.
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